Phase I Pilot Study of CD34 Enriched, Fanconi's Anemia Complementation Group C Gene Transduced Autologous Peripheral Blood Stem Cell Transplantation in Patients With Fanconi's Anemia
This trial is active, not recruiting.
|Treatments||filgrastim, autologous stem cells transduced with facc retroviral vector, autologous stem cell transplantation|
|Sponsor||University of Minnesota - Clinical and Translational Science Institute|
|Start date||March 2000|
|Trial size||6 participants|
|Trial identifier||NCT00005896, 199/15107, UMN-MT-1997-10, UNM-MT-9710|
OBJECTIVES: I. Determine the safety of transferring the Fanconi anemia complementation group C (FACC) gene to hematopoietic progenitors by retroviral mediated gene transfer in patients with Fanconi's anemia, complementation group C.
II. Determine the extent of engraftment following this treatment regimen without prior ablation of recipient marrow in these patients.
III. Determine the ability of this treatment regimen to correct the cell phenotype and improve hematopoietic function in these patients.
Male or female participants at least 5 years old.
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Fanconi's anemia, complementation group C (FACC) Confirmed by diepoxybutane or mitomycin testing AND DNA analysis indicating FACC mutations - Patients at least 25 kg weight - No acute leukemia OR Bone marrow aspirate with greater than 10% blasts - No patients who elect bone marrow transplantation --Prior/Concurrent Therapy-- - At least 14 days since prior therapy for any acute viral, bacterial, or fungal infection --Patient Characteristics-- - Performance status: Karnofsky 40-100% - Hepatic: SGOT, SGPT, and alkaline phosphatase no greater than 5 times upper limit of normal (ULN) PT/PTT no greater than 1.5 times ULN Serum amylase no greater than 1.5 times ULN Bilirubin no greater than 2.5 mg/dL Triglyceride less than 400 mg/dL - Renal: Creatinine clearance greater than 50 mL/min - Cardiovascular: Normal cardiac function No ischemic heart disease that may be considered an anesthetic or operative risk - Pulmonary: No lung disease that may be considered an anesthetic or operative risk Resting transcutaneous oxygen saturation greater than 90% on room air - Other: HIV negative Hepatitis B surface antigen negative No underlying condition that may preclude study therapy (e.g., allergies to study reagents) - No acute viral, bacterial, or fungal infection Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception
|Description||PROTOCOL OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously daily on days 0-6 followed by apheresis to collect peripheral blood stem cells (PBSC) on days 5-7. PBSCs are processed in vitro for enrichment of CD34 cells and transduced with a Fanconi's anemia complementation C (FACC) retroviral vector on days 5-10. Patients receive transduced PBSCs IV over no more than 2 hours on days 8-10. PBSC infusions may be repeated no more than every 2 months for up to 4 courses total. Patients are followed monthly for 3 months, every 3 months for 9 months, every 6 months for the next year, and then yearly thereafter.|
Call for more information